

# FIGURE 1 OF 6

Table 1

Patient	Nationality	Age	Duration	B51 101	Disease Activity	Immunosuppr. Treatment	Dose of p336-351- CTB	1 <sup>o</sup> Ocular Result after all treatment withdrawn
1	Middle Eastern (Turkish)	35	4 yrs	+	Nil	5-7.5mg Predn. 150mg Azath.	0.5mg	No relapse, maintained 15 months
2	Caucasian (Irish)	36	13 yrs	+	Nil	10mg Predn. (No Azath)	5mg	No relapse, maintained 12 months
3	Caucasian (English)	35	1 yr	+	Nil	10-15mg Predn. 150mg Azath.	0.5mg	No relapse after 10 months
4	Caucasian (Irish)	36	12 yrs	+	Nil	10mg Predn. 100mg Azath.	0.5mg	Relapse after 1 month
5	Caucasian (English)	30	2 yrs	?	Nil	10mg Predn. 1.5mg Colchicine	5mg	Relapse after 2 wks
6	Middle Eastern (Iraqi)	51	>13 yrs	+	Nil	5mg Predn.	0.5mg	Relapse within a day of 2.5mg Predn. On alternate days
7	Caucasian (English)	29	6 yrs	+	Severe pustules inflam. cells In ant. chamber,	15mg Predn. 400mg Cyclosporin	5mg	Relapse within 2 wks of reducing of Cyclosp.
8	Caucasian (English)	34	6 yrs	-	RAS and Folliculitis	15mg Predn. 2mg CellCept	5mg	Relapse within a day of reducing Predn;

# FIGURE 2 OF 6

Table 2 Phenotypic analysis of PBMC in the two groups of patients with BD in whom uveitis was either prevented or relapsed during and after the change from immunosuppressive drugs to p336-351-CTB tolerizing regime

UVEITIS PREVENTED (mean $\pm$ sem)			UVEITIS RELAPSED (mean $\pm$ sem)		
Cell Marker	Change	Before 3 months**	After 6-9 months***	Change	Before 1-2 months
(A) Inverse Relationship					
CD4	Decrease	42.8 (3.4)	26.4 (2.2)	Increase	28.6 (8.6)
CCR5	Decrease	7.3 (1.5)	5.9 (0.9)	Increase	8.0 (1.8)
CXCR3	Decrease	20.6 (5.3)	14.9 (0.6)	Increase	14.4
CCR7	Decrease	36.3 (6.2)	27.5 (4.8)	Increase	6.4
CXCR4	Increase	14.6 (5.9)	17.8 (3.4)	Decrease	24.3 (12.7)
CD28	Decrease	33.2 (9.9)	13.6 (4.7)	Increase	30.1 (10.2)
CD40	Decrease	58.1 (14.7)	37.0 (5.7)	Increase	25.3 (5.6)
(B) No Inverse Relationship					
TCR- $\gamma\delta$	Decrease	4.9 (1.0)	2.3 (0.8)	No change	2.9 (0.6)
CCR6	Decrease	9.0 (1.8)	3.7 (1.8)	No change	2.6 (0.4)
CD86	Increase	9.6 (2.6)	16.4 (2.1)	Decrease	4.5 (2.0)
No distinguishing pattern					
CD8, CD45RA, CD45RO, CCR3 showed					
***of 3 patients who showed no relapse up to 10 months					
**at the end of tolerization					

FIGURE 3 OF 6




Fig 1a




Fig1b


Figure 1. Optical coherence images of the fovea (4mm horizontal scan) of a) patient in remission off all immunosuppressive treatment and b) patient in relapse. The retina is markedly thickened and shows black cystic spaces consistent with cystoid macular oedema.

BEST AVAILABLE COPY

# FIGURE 4 OF 6


Fig 2

**T cell proliferative responses stimulated with p336-351 or 136-151 (A) and HSP65 (B) before (0) and after oral tolerance was completed (3 months) and at the end of observation (9+ months) in 5 patients in whom uveitis was prevented and 3 patients with relapsing uveitis.**



# FIGURE 5 OF 6

Fig 3 Phenotypic analysis of 6 cell-surface markers  
□ before and ▨ after the t lerizing r gime.



NOT AVAILABLE COPY

FIGURE 6 OF 6

743 The effect of stimulating PBMC with p336-351 on the production of  $\text{IFN-}\gamma$  and  $\text{TNF-}\alpha$

